PTPRC is an immunotherapeutic predictor and serum biomarker in lung adenocarcinoma correlated with immune cell infiltration

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, with the poor overall prognosis. PTPRC is an essential protein on the surface of cells of the immunological systems However, the role of PTPRC in LUAD has not been clarified. UALCAN, HPA and TCGA database were used to investigate PTPRC expression in LUAD. HPA and Kaplan-Meier plotter database were used to explore the survival curve evaluating the prognostic value of PTPRC for LUAD. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis of PTPRC co-expression genes downloaded from cBioPortal database. Tumor immune dysfunction and exclusion (TIDE) was used to predict the immunotherapy response in different PTPRC subgroups. TIMER was used to analyze the correlation of PTPRC and immune cell infiltration or immune checkpoint expression level in LUAD. Serum PTPRC were detected by enzyme linked immunosorbent assay. In present study, the expression of PTPRC in LUAD was lower than that in the normal control group by means of bioinformatics analysis of the TCGA and UALCAN public databases. Moreover, LUAD patients with downregulated PTPRC expression exhibited poor overall survival. Besides, PTPRC was significantly positively correlated with various immune cells in LUAD. TIDE scores were markedly elevated in the PTPRC low-expression subgroup in contrast to the PTPRC high-expression subgroup, And PTPRC was also markedly positively associated with biomarkers of these infiltrated immune cells. PTPRC expression was also positively correlated with PD-1, PD-L1 and CTLA-4 expression. The serum PTPRC levels in LUAD patients were significantly reduced compared to the normal health group. The ROC curve of PTPRC concentration in LUAD was plotted to obtain an AUC = 0.7887, the cutoff value was 31.55 pg/mL, and the sensitivity and specificity were 77.78 and 70.00%, respectively. In summary, our results indicate that down-regulation of PTPRC predicts poor prognosis and associated with immune infiltration in LUAD and PTPRC is an immunotherapeutic predictor and serum biomarker in LUAD correlated with immune cell infiltration.